Skip to main content
Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression
Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After ProgressionNews & Conference Highlights

Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression

April 2, 2026
Navigating Second-Line Treatment Decisions in EGFR+ NSCLC
Navigating Second-Line Treatment Decisions in EGFR+ NSCLCExpert Insights

Navigating Second-Line Treatment Decisions in EGFR+ NSCLC

April 1, 2026
Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC
Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLCNews & Conference Highlights

Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC

March 30, 2026
Dato-DXd Confers Clinical Benefit Regardless of TROP2 NMR Status in EGFR-Mutant NSCLC
Dato-DXd Confers Clinical Benefit Regardless of TROP2 NMR Status in EGFR-Mutant NSCLCNews & Conference Highlights

Dato-DXd Confers Clinical Benefit Regardless of TROP2 NMR Status in EGFR-Mutant NSCLC

March 27, 2026
Sac-TMT Extends OS in Pretreated EGFR-Mutated NSCLC
Sac-TMT Extends OS in Pretreated EGFR-Mutated NSCLCNews & Conference Highlights

Sac-TMT Extends OS in Pretreated EGFR-Mutated NSCLC

March 27, 2026
Adding LCT to Osimertinib Improves PFS Outcomes, Local Control Rates in EGFR-Mutated NSCLC
Adding LCT to Osimertinib Improves PFS Outcomes, Local Control Rates in EGFR-Mutated NSCLCNews & Conference Highlights

Adding LCT to Osimertinib Improves PFS Outcomes, Local Control Rates in EGFR-Mutated NSCLC

March 26, 2026
Osimertinib Plus Chemotherapy Doubles PFS in EGFR-, TP53-Mutant Advanced NSCLC
Osimertinib Plus Chemotherapy Doubles PFS in EGFR-, TP53-Mutant Advanced NSCLCNews & Conference Highlights

Osimertinib Plus Chemotherapy Doubles PFS in EGFR-, TP53-Mutant Advanced NSCLC

March 26, 2026
How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLC
How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLCExpert Insights

How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLC

March 26, 2026
Ongoing Research to Watch in EGFR-Mutated NSCLC
Ongoing Research to Watch in EGFR-Mutated NSCLCExpert Insights

Ongoing Research to Watch in EGFR-Mutated NSCLC

March 13, 2026
Remaining Evidence Gaps in EGFR-Mutated NSCLC Care
Remaining Evidence Gaps in EGFR-Mutated NSCLC CareExpert Insights

Remaining Evidence Gaps in EGFR-Mutated NSCLC Care

March 13, 2026
Experiences With ADCs in EGFR-Mutated NSCLC Management
Experiences With ADCs in EGFR-Mutated NSCLC ManagementExpert Insights

Experiences With ADCs in EGFR-Mutated NSCLC Management

March 13, 2026
Resistance Mechanisms in EGFR-Mutated NSCLC
Resistance Mechanisms in EGFR-Mutated NSCLCExpert Insights

Resistance Mechanisms in EGFR-Mutated NSCLC

March 13, 2026
Evolving Frontline Treatment Options in EGFR-Mutated NSCLC
Evolving Frontline Treatment Options in EGFR-Mutated NSCLCExpert Insights

Evolving Frontline Treatment Options in EGFR-Mutated NSCLC

March 13, 2026
Sequencing Considerations in Advanced EGFR-Mutated NSCLC
Sequencing Considerations in Advanced EGFR-Mutated NSCLCExpert Insights

Sequencing Considerations in Advanced EGFR-Mutated NSCLC

March 13, 2026
Risk Factors That Help Inform Treatment Selection in Frontline EGFR-Mutated NSCLC
Risk Factors That Help Inform Treatment Selection in Frontline EGFR-Mutated NSCLCExpert Insights

Risk Factors That Help Inform Treatment Selection in Frontline EGFR-Mutated NSCLC

March 13, 2026
Toxicity Considerations With ADCs and Other Approaches in EGFR-Mutated NSCLC
Toxicity Considerations With ADCs and Other Approaches in EGFR-Mutated NSCLCExpert Insights

Toxicity Considerations With ADCs and Other Approaches in EGFR-Mutated NSCLC

March 6, 2026
How Frontline Therapy Affects Sequencing Considerations in EGFR-Mutated NSCLC
How Frontline Therapy Affects Sequencing Considerations in EGFR-Mutated NSCLCExpert Insights

How Frontline Therapy Affects Sequencing Considerations in EGFR-Mutated NSCLC

March 6, 2026
AE Management With Subcutaneous Amivantamab in EGFR-Mutated NSCLC
AE Management With Subcutaneous Amivantamab in EGFR-Mutated NSCLCExpert Insights

AE Management With Subcutaneous Amivantamab in EGFR-Mutated NSCLC

February 27, 2026
The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management
The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC ManagementExpert Insights

The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management

February 27, 2026
Navigating Treatment Decisions for EGFR-Mutated NSCLC With High-Risk Features
Navigating Treatment Decisions for EGFR-Mutated NSCLC With High-Risk FeaturesExpert Insights

Navigating Treatment Decisions for EGFR-Mutated NSCLC With High-Risk Features

February 20, 2026
Factors Driving Frontline Treatment Selection in EGFR-Mutated NSCLC
Factors Driving Frontline Treatment Selection in EGFR-Mutated NSCLCExpert Insights

Factors Driving Frontline Treatment Selection in EGFR-Mutated NSCLC

February 20, 2026
Updated OS Data Reshape First- and Second-Line Treatment Selection in EGFR-Mutated Advanced NSCLC
Updated OS Data Reshape First- and Second-Line Treatment Selection in EGFR-Mutated Advanced NSCLCNews & Conference Highlights

Updated OS Data Reshape First- and Second-Line Treatment Selection in EGFR-Mutated Advanced NSCLC

December 22, 2025
FDA Approves Subcutaneous Amivantamab for EGFR+ NSCLC
FDA Approves Subcutaneous Amivantamab for EGFR+ NSCLCNews & Conference Highlights

FDA Approves Subcutaneous Amivantamab for EGFR+ NSCLC

December 18, 2025
EGFR-Mutated NSCLC: Using Post-Progression Data to Guide 1L Strategies
EGFR-Mutated NSCLC: Using Post-Progression Data to Guide 1L StrategiesExpert Insights

EGFR-Mutated NSCLC: Using Post-Progression Data to Guide 1L Strategies

December 3, 2025
EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Patient Factors
EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Patient FactorsExpert Insights

EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Patient Factors

December 3, 2025
EGFR-Mutated NSCLC: Refining Patient Selection for Monotherapy vs Combination Therapy
EGFR-Mutated NSCLC: Refining Patient Selection for Monotherapy vs Combination TherapyExpert Insights

EGFR-Mutated NSCLC: Refining Patient Selection for Monotherapy vs Combination Therapy

December 3, 2025
Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc
Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MScEmerging Voices in EGFR Care

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc

November 14, 2025
NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated Disease
NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated DiseaseNews & Conference Highlights

NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated Disease

November 10, 2025
Osimertinib Plus Chemo Outperforms Single-Agent Osimertinib Regardless of Prognostic Factors in EGFR+ NSCLC
Osimertinib Plus Chemo Outperforms Single-Agent Osimertinib Regardless of Prognostic Factors in EGFR+ NSCLCNews & Conference Highlights

Osimertinib Plus Chemo Outperforms Single-Agent Osimertinib Regardless of Prognostic Factors in EGFR+ NSCLC

October 29, 2025
FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLC
FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLCExpert Insights

FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLC

October 27, 2025
MARIPOSA-2 Toxicity Management: Amivantamab Delay vs Dose Reduction
MARIPOSA-2 Toxicity Management: Amivantamab Delay vs Dose ReductionExpert Insights

MARIPOSA-2 Toxicity Management: Amivantamab Delay vs Dose Reduction

October 27, 2025
Continuing Osimertinib in the 2L Treatment Setting: Data From COMPEL
Continuing Osimertinib in the 2L Treatment Setting: Data From COMPELExpert Insights

Continuing Osimertinib in the 2L Treatment Setting: Data From COMPEL

October 27, 2025
Dr. Jänne on OS Benefit With Osimertinib Plus Chemo by Poor Prognostic Factors in EGFR+ NSCLC
Dr. Jänne on OS Benefit With Osimertinib Plus Chemo by Poor Prognostic Factors in EGFR+ NSCLCExpert Insights

Dr. Jänne on OS Benefit With Osimertinib Plus Chemo by Poor Prognostic Factors in EGFR+ NSCLC

October 20, 2025
Pemetrexed Maintenance Duration and Toxicity Management
Pemetrexed Maintenance Duration and Toxicity ManagementExpert Insights

Pemetrexed Maintenance Duration and Toxicity Management

October 20, 2025
Dr. Passaro on the Role of MET in Guiding Treatment Strategies After EGFR TKI Progression in NSCLC
Dr. Passaro on the Role of MET in Guiding Treatment Strategies After EGFR TKI Progression in NSCLCExpert Insights

Dr. Passaro on the Role of MET in Guiding Treatment Strategies After EGFR TKI Progression in NSCLC

October 16, 2025
The Impact of SKIPirr and COCOON Protocols on Amivantamab Toxicities
The Impact of SKIPirr and COCOON Protocols on Amivantamab ToxicitiesExpert Insights

The Impact of SKIPirr and COCOON Protocols on Amivantamab Toxicities

October 13, 2025
Differentiating Between the Risk-Benefit Profiles for the Combination Therapies
Differentiating Between the Risk-Benefit Profiles for the Combination TherapiesExpert Insights

Differentiating Between the Risk-Benefit Profiles for the Combination Therapies

October 13, 2025
Identifying High-risk Patient Populations Benefitting From Combination Therapy in the Frontline
Identifying High-risk Patient Populations Benefitting From Combination Therapy in the FrontlineExpert Insights

Identifying High-risk Patient Populations Benefitting From Combination Therapy in the Frontline

September 22, 2025
Intracranial Efficacy of Datopotamab Deruxtecan (DatoDXd) in Patients With Advanced/Metastatic NSCLC in TROPION-Lung01
Intracranial Efficacy of Datopotamab Deruxtecan (DatoDXd) in Patients With Advanced/Metastatic NSCLC in TROPION-Lung01Expert Insights

Intracranial Efficacy of Datopotamab Deruxtecan (DatoDXd) in Patients With Advanced/Metastatic NSCLC in TROPION-Lung01

September 19, 2025
First-Line Osimertinib Chemo vs Osimertinib Mono in EGFRm Advanced NSCLC: Flaura2 Final Overall Survival
First-Line Osimertinib Chemo vs Osimertinib Mono in EGFRm Advanced NSCLC: Flaura2 Final Overall SurvivalExpert Insights

First-Line Osimertinib Chemo vs Osimertinib Mono in EGFRm Advanced NSCLC: Flaura2 Final Overall Survival

September 18, 2025
Dato-DXd Leads to Intracranial Responses in Advanced/Metastatic NSCLC With Brain Metastases
Dato-DXd Leads to Intracranial Responses in Advanced/Metastatic NSCLC With Brain MetastasesNews & Conference Highlights

Dato-DXd Leads to Intracranial Responses in Advanced/Metastatic NSCLC With Brain Metastases

September 8, 2025
Continuing Osimertinib Plus Chemo After Progression Improves PFS in EGFR-Mutated NSCLC
Continuing Osimertinib Plus Chemo After Progression Improves PFS in EGFR-Mutated NSCLCNews & Conference Highlights

Continuing Osimertinib Plus Chemo After Progression Improves PFS in EGFR-Mutated NSCLC

September 6, 2025
Dr. Lopes on a Cost Analysis of Osimertinib/Chemo vs Amivantamab/Lazertinib in EGFR+ NSCLC
Dr. Lopes on a Cost Analysis of Osimertinib/Chemo vs Amivantamab/Lazertinib in EGFR+ NSCLCExpert Insights

Dr. Lopes on a Cost Analysis of Osimertinib/Chemo vs Amivantamab/Lazertinib in EGFR+ NSCLC

July 30, 2025
Understanding Underlying Resistance Mechanisms is Vital for Guiding Treatment Selection Post-Osimertinib in EGFR+ NSCLC
Understanding Underlying Resistance Mechanisms is Vital for Guiding Treatment Selection Post-Osimertinib in EGFR+ NSCLCNews & Conference Highlights

Understanding Underlying Resistance Mechanisms is Vital for Guiding Treatment Selection Post-Osimertinib in EGFR+ NSCLC

July 25, 2025
Dr. Halmos on the FDA Approval of Dato-DXd for Advanced/Metastatic EGFR-Mutated NSCLC
Dr. Halmos on the FDA Approval of Dato-DXd for Advanced/Metastatic EGFR-Mutated NSCLCExpert Insights

Dr. Halmos on the FDA Approval of Dato-DXd for Advanced/Metastatic EGFR-Mutated NSCLC

June 23, 2025
Neoadjuvant Osimertinib Yields MPRs With or Without Chemotherapy in Resectable EGFR-Mutated NSCLC
Neoadjuvant Osimertinib Yields MPRs With or Without Chemotherapy in Resectable EGFR-Mutated NSCLCNews & Conference Highlights

Neoadjuvant Osimertinib Yields MPRs With or Without Chemotherapy in Resectable EGFR-Mutated NSCLC

June 3, 2025
COCOON DM Regimen Reduces Amivantamab/Lazertinib Effects on QOL in EGFR-Mutated NSCLC
COCOON DM Regimen Reduces Amivantamab/Lazertinib Effects on QOL in EGFR-Mutated NSCLCNews & Conference Highlights

COCOON DM Regimen Reduces Amivantamab/Lazertinib Effects on QOL in EGFR-Mutated NSCLC

June 2, 2025
Amivantamab Plus Chemo Maintains PFS Benefit in EGFR+ NSCLC Regardless of Osimertinib Resistance Mechanism
Amivantamab Plus Chemo Maintains PFS Benefit in EGFR+ NSCLC Regardless of Osimertinib Resistance MechanismNews & Conference Highlights

Amivantamab Plus Chemo Maintains PFS Benefit in EGFR+ NSCLC Regardless of Osimertinib Resistance Mechanism

May 31, 2025
Dr. Califano on MARIPOSA-2 Outcomes by Baseline Resistance Mechanisms in EGFR+ NSCLC
Dr. Califano on MARIPOSA-2 Outcomes by Baseline Resistance Mechanisms in EGFR+ NSCLCExpert Insights

Dr. Califano on MARIPOSA-2 Outcomes by Baseline Resistance Mechanisms in EGFR+ NSCLC

May 31, 2025
56-Year-Old Never-Smoker Female with High-Risk Metastatic EGFR-Mutant NSCLC Treated with the FLAURA2 Regimen
56-Year-Old Never-Smoker Female with High-Risk Metastatic EGFR-Mutant NSCLC Treated with the FLAURA2 RegimenHow I Treat

56-Year-Old Never-Smoker Female with High-Risk Metastatic EGFR-Mutant NSCLC Treated with the FLAURA2 Regimen

May 2, 2025
Osimertinib After Definitive Chemoradiotherapy in Patients with Unresectable Stage III EGFRm NSCLC: Updated Overall Survival Analysis From the LAURA Study
Osimertinib After Definitive Chemoradiotherapy in Patients with Unresectable Stage III EGFRm NSCLC: Updated Overall Survival Analysis From the LAURA StudyNews & Conference Highlights

Osimertinib After Definitive Chemoradiotherapy in Patients with Unresectable Stage III EGFRm NSCLC: Updated Overall Survival Analysis From the LAURA Study

April 16, 2025
Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies
Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management StrategiesExpert Insights

Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies

November 5, 2024
Intracranial Efficacy of Datopotamab Deruxtecan in Patients With Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From TROPION-Lung05
Intracranial Efficacy of Datopotamab Deruxtecan in Patients With Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From TROPION-Lung05Expert Insights

Intracranial Efficacy of Datopotamab Deruxtecan in Patients With Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From TROPION-Lung05

June 27, 2024
Dato-DXd Demonstrates Intracranial Activity in Advanced NSCLC With/Without Brain Metastases
Dato-DXd Demonstrates Intracranial Activity in Advanced NSCLC With/Without Brain MetastasesNews & Conference Highlights

Dato-DXd Demonstrates Intracranial Activity in Advanced NSCLC With/Without Brain Metastases

June 3, 2024

Funding for the EGFR Channel is provided by AstraZeneca. All content is developed independently by MJH Life Sciences; AstraZeneca has no influence on the content of the site.

© 2026 MJH Life Sciences. All rights reserved.

Home
Clinical Updates Calendar
View All Resources